Production of non-fucosylated antibodies by co-expression of heterologous GDP-6-deoxy-D-lyxo-4-hexulose reductase

Glycobiology
Hans Henning von HorstenVolker Sandig

Abstract

All IgG-type antibodies are N-glycosylated in their Fc part at Asn-297. Typically, a fucose residue is attached to the first N-acetylglucosamine of these complex-type N-glycans. Antibodies lacking core fucosylation show a significantly enhanced antibody-dependent cell-mediated cytotoxicity (ADCC) and an increased efficacy of anti-tumor activity. In cases where the clinical efficacy of an antibody is to some extent mediated by its ADCC effector function, afucosylated N-glycans could help to reduce dose requirement and save manufacturing costs. Using Chinese hamster ovary (CHO) cells as a model, we demonstrate here that heterologous expression of the prokaryotic enzyme GDP-6-deoxy-d-lyxo-4-hexulose reductase within the cytosol can efficiently deflect the fucose de novo pathway. Antibody-producing CHO cells that were modified in this way secrete antibodies lacking core fucose as demonstrated by MALDI-TOF mass spectrometry and HPAEC-PAD monosaccharide analysis. Engineering of the fucose de novo pathway has led to the construction of IgGs with a strongly enhanced ADCC effector function. The method described here should have broad practical applicability for the development of next-generation therapeutic antibodies.

References

Jan 1, 1989·Proceedings of the National Academy of Sciences of the United States of America·J M Sedivy, P A Sharp
Nov 1, 1986·Somatic Cell and Molecular Genetics·G UrlaubJ Hamlin
Aug 6, 1998·Annals of Hematology·J E GessnerR E Schmidt
Oct 15, 1998·Bulletin du cancer·S Faivre
Apr 12, 2001·The Journal of Biological Chemistry·S RadaevP D Sun
May 8, 2003·Journal of the American Chemical Society·Noelle BeyerHung-wen Liu
Jan 24, 2004·Protein Science : a Publication of the Protein Society·Nicole A WebbR Michael Garavito
Sep 28, 2004·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Rinpei NiwaKenya Shitara
Oct 30, 2004·Biotechnology and Bioengineering·Katsuhiro MoriMitsuo Satoh
Mar 25, 2005·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Rinpei NiwaKenya Shitara
Apr 13, 2006·Biotechnology and Bioengineering·Yutaka KandaMitsuo Satoh
Mar 17, 2007·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Eiji SuzukiMasakazu Toi
Dec 12, 2007·Proteomics·Kai MaassRudolf Geyer
Jan 19, 2008·FEBS Letters·Christoph Albermann, Holger Beuttler
Mar 4, 2008·Journal of Proteome Research·Alessio CeroniStuart M Haslam
Mar 19, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Antonino MusolinoAndrea Ardizzoni
Dec 5, 2008·Journal of the American Chemical Society·Stephen T B Lau, Martin E Tanner
Jan 28, 2010·Molecular & Cellular Proteomics : MCP·Damian HoudeJohn R Engen

❮ Previous
Next ❯

Citations

Oct 13, 2012·Anti-cancer Drugs·Jay J ListinskyCatherine M Listinsky
Mar 1, 2012·BMC Proceedings·Hans Henning von HorstenVolker Sandig
Nov 3, 2015·Biotechnology Advances·Simon FischerKerstin Otte
Nov 23, 2012·Biotechnology Progress·Seshu TummalaAnthony Rossomando
Apr 3, 2016·Current Opinion in Immunology·Peter Sondermann, David E Szymkowski
Dec 20, 2014·Proteomics·Stefan WeizVéronique Blanchard
May 15, 2015·Biotechnology Letters·Huong LeWei-Shou Hu
Jul 16, 2013·Methods : a Companion to Methods in Enzymology·Christian KellnerMatthias Peipp
Jul 10, 2014·Current Opinion in Biotechnology·Michael Butler, Maureen Spearman
Oct 23, 2016·Biotechnology Progress·Thomas K VilligerMiroslav Soos
Nov 12, 2016·World Journal of Microbiology & Biotechnology·Amjad Hayat KhanAzam Rahimpour
Nov 23, 2016·Scientific Reports·Gillian DekkersGestur Vidarsson
Feb 20, 2018·Biotechnology and Bioengineering·Qiong WangMichael J Betenbaugh
Dec 17, 2017·Biotechnology Journal·Venkata S Tayi, Michael Butler
Oct 27, 2017·Transfusion Medicine and Hemotherapy : Offizielles Organ Der Deutschen Gesellschaft Fur̈ Transfusionsmedizin Und Immunham̈atologie·Christian KellnerMatthias Peipp
Nov 29, 2017·Frontiers in Immunology·Wei LiDimiter S Dimitrov
Sep 29, 2018·Current Protocols in Protein Science·Molly HunterMark Fox
Feb 12, 2017·Journal of Industrial Microbiology & Biotechnology·Arpan A BandyopadhyayWei-Shou Hu
Oct 20, 2018·Cellular and Molecular Life Sciences : CMLS·Thomas SchlakeIngo Jordan
Mar 28, 2019·Annual Review of Biochemistry·Lai-Xi WangTiezheng Li
Nov 30, 2015·Bioengineering·Julia RosenlöcherStephan Hinderlich
Nov 19, 2017·Biotechnology and Bioengineering·Ronan M KellyChristopher C Frye
May 4, 2017·BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy·Xiaojie YuMax Crispin
Jul 7, 2019·Biotechnology Advances·Kritika GuptaPrajakta Dandekar
Oct 26, 2018·Emerging Topics in Life Sciences·Qiong Wang, Michael J Betenbaugh
Mar 12, 2021·Biochemical Society Transactions·Roberto DoniniCleo Kontoravdi
Jul 3, 2021·International Journal of Molecular Sciences·Catherine Forest-NaultGregory De Crescenzo
Jul 14, 2011·Chemical Reviews·Ryan M SchmaltzChi-Huey Wong

❮ Previous
Next ❯

Related Concepts

Related Feeds

Adrenocortical Carcinoma

Adrenocortical carcinoma (ACC) is a rare malignancy of the adrenal cortex, associated with a generally dismal prognosis owing to its aggressive behavior. Here are the latest discoveries pertaining to this disease.

Antibody-Dependent Cell Cytotoxicity

Antibody-dependent cellular toxicity refers to the lysis of a target cell by a non-sensitized effector cell of the immune system as a result of antibodies binding to the target cell membrane and engaging the Fc receptors on the immune effector cells. Find the latest research on antibody-dependent cellular toxicity here.